MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$7,314K
Proceeds from sale of
marketable securities
$296K
Proceeds from equity line
of credit
$398K
Net cash provided by
financing activities
$6,654K
Net cash provided by
investing activities
$296K
Canceled cashflow
$1,058K
Net increase
(decrease) in cash and cash...
$1,871K
Canceled cashflow
$5,079K
Repayment of debt with cash
$660K
Proceeds from sale of
stock, net of issuance...
-$398K
Loss on issuance of
warrants
-$3,977K
Accrued expenses
$287K
Abandonment and expiration
of patents and...
$82K
Amortization of financial
obligation
$69K
Non-cash lease expense
-$59K
Amortization of patent,
trademark rights
$45K
Prepaid expenses and
other current assets
-$24K
Depreciation of property and
equipment
$9K
Net cash used in
operating activities
-$5,079K
Canceled cashflow
$4,552K
Net loss
-$3,284K
Non-cash gain on
settlement of liability
-$3,041K
Accounts payable
-$2,570K
Change in fair value of
warrants
-$670K
Lease liability
-$56K
Gain on sale of
marketable securities
$17K
Back
Back
Cash Flow
source: myfinsight.com
AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc. (AIM)